Pharmaceutical company Glenmark Generics has confirmed that it has filed ANDAs with the US FDA to market generic versions of epilepsy drug Vimpat.
The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.
Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Pharmaceutical company Merck has secured a preliminary injunction against Indian drug company Aprica after it tried to market generic versions of the branded diabetes drug Januvia.
Global drug companies Actavis and Teva both launched generic versions of Viagra immediately after its patent expired in several European countries last week.
The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.
A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.